Redwood City, United States
Bolt Biotherapeutics, Inc., founded in 2015 and headquartered in the United States, is a biotechnology firm focused on developing cutting-edge T-cell mediated anti-tumor therapy. The company's proprietary technology, Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), demonstrates significant potential as an innovative class of immuno-oncology therapeutics. Preclinical studies indicate these therapeutics can effectively eliminate tumors and develop immunological memory, providing more durable clinical responses.
This technology's adaptability allows it to target tumor antigens across diverse cancer types, including those unresponsive to current checkpoint inhibitors. Bolt Biotherapeutics was founded by Dr. Ed Engleman, with their platform based on technology licensed from Stanford University.
The company's leadership brings a wealth of oncology drug discovery expertise. Supported by prominent investors such as Novo Holdings, Pivotal bioVenture Partners, Vivo Capital, and Nan Fung Life Sciences, Bolt Biotherapeutics secured a $230.00M IPO investment on 01 February 2021.
Sumitomo Pharma Oncology